Trastuzumab is an anti-HER monoclonal antibody given intravenously with a loading dose of 8 mg/kg or 4 mg/kg to be followed by maintenance dosing of 2 mg/ kg weekly or 6 mg/kg every three weeks. 1 Trastuzumab therapy for breast cancer is usually prolonged, with one year of adjuvant treatment [2] [3] [4] [5] [6] and potentially longer in the metastatic setting when it is usually given until progression. 7 Therefore, delays in dosing are not uncommon, leading to concerns of subtherapeutic serum level and the need for a reloading dose. The timing of the reloading dose, however, depends on what serum level to be targeted and the elimination half-life of trastuzumab.
The HERCEPTIN Õ monograph recommends a reloading dose after a delay of more than 1-2 weeks. 1 Based on communication with the Drug Information of Hoffmann-La Roche Limited, this recommendation is based on in-house simulation studies for a 70 kg person using a two compartmental model and estimates from the population pharmacokinetic analysis of the collective phase I/II data of weekly trastuzumab therapy. Assuming delays of 1 and 2 weeks, simulations performed for weekly and three-weekly dosing showed that it took more than six and nine weeks for serum level to return to within 5% of the steady state of 50 mg/mL, respectively. However, it is unclear of the need to maintain a level of 50 mg/mL for efficacy.
In phase II trials, the mean serum trough level was 50-70 mg/mL [8] [9] [10] [11] with steady state level at 50-60 mg/mL. 8, 9 However, dosing used in phase III trials was based on phase I/II studies with targeted serum levels of >10 mg/mL, 12,13 10-20 mg/mL 9,14,15 and >20 mg/mL. 10 These targeted levels were in turn based on vitro data suggesting maximum antiproliferative effect on Sk-Br-3 cells with HER2 overexpression with concentration of approximately >10 mg/mL. 10, 13, 16, 17 The exact concentration for maximum inhibition, however, is not clear. For example, the study by Carter et al. 16 seemed to plateau at 8-10 mg/mL, while Tokuda et al. 13 suggested plateauing at 0.1-1.0 mg/mL from their data. However, subsequent clinical trials generally aimed for serum levels of >10-20 mg/mL 9,10,12-15 and none was designed to achieve >50 mg/mL. A steady state of serum level is reached for the weekly and three-weekly dosing after 20 and 12 weeks, respectively. 1 Given the long elimination half-life of trastuzumab (29 days with weekly dosing, 18 18-27 days with three-weekly dosing), 10 a delay of 1-2 weeks after steady state has been reached seems unlikely to result in the serum level falling below 10-20 mg/mL. 9,10,12-14 For example, a serum level of 50 mg/mL would decline to 25, 19 and 13 mg/mL after a delay of four, six and eight weeks, respectively, assuming a half-life of around four weeks (28 days). Therefore, reloading is probably only needed after a delay of more than six weeks and is likely necessary if longer than eight weeks.
